simvastatin / Generic mfg. - LARVOL DELTA

Effect of Alginate Coatings on Hydroxyapatite/β-Tricalcium Phosphate Scaffold Behavior. (PubMed, J Funct Biomater) - "HA/β-TCP scaffolds were loaded with simvastatin (SIMV) and coated with multiple layers of alginate (ALG)...Moreover, ALG deposition improved the micromechanical properties of the scaffolds, conferring a dual structure analogous to those of bone tissue. These findings indicate that ALG-coated SIMV-loaded HA/β-TCP scaffolds represent a promising multifunctional platform for the medical field."

Journal • Dental Disorders • Infectious Disease • Musculoskeletal Diseases • Osteoporosis • Periodontitis

Statin-Ezetimibe Attenuates Hepatic Inflammation and Fibrosis in a Diet- and Toxin-Induced Steatohepatitis Model, Associated with Macrophage NF-κB Inhibition. (PubMed, Cells) - "Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of adults globally; its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), has limited pharmacological options beyond the recently approved resmetirom...Simvastatin (5 mg/kg) and/or Ezetimibe (10 mg/kg) were added to the diet for 4 weeks... Statin-Ezetimibe combination exerts anti-inflammatory and anti-fibrotic effects in a multi-hit murine model of MASH with advanced fibrosis associated with macrophage NF-κB inhibition in vitro and with reduced hepatic inflammatory signaling in vivo. These findings provide mechanistic rationale for the hepatic benefits of this widely used regimen in MASH patients with dyslipidemia, supporting its evaluation as a drug-repurposing strategy."

Journal • Dyslipidemia • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • IL1B • IL6 • TGFB1 • TNFA

Comparative efficacy of locally delivered 1.2% rosuvastatin and 1.2% simvastatin gel as an adjunct to non-surgical periodontal therapy in chronic periodontitis: a clinical and microbiological assay. (PubMed, Saudi Dent J) - "The local delivery of both 1.2% simvastatin gel and 1.2% rosuvastatin gel as adjuncts to non-surgical periodontal therapy significantly improved clinical and microbiological outcomes in chronic periodontitis. While simvastatin demonstrated slightly greater absolute improvements than rosuvastatin, the overall therapeutic difference between the two statins was not statistically significant."

Journal • Dental Disorders • Periodontitis

The Role of Bisphosphonate and Simvastatin Combination on Therapeutic Response in Breast Cancer With Bone Metastasis Via Dicckopf-1 Pathway (clinicaltrials.gov) - P=N/A | N=35 | Completed | Sponsor: Indonesia University

New trial • Breast Cancer • Oncology • Solid Tumor • DKK1 • TRAP

The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: Universitas Indonesia | Trial completion date: Aug 2025 ➔ Dec 2026 | Trial primary completion date: May 2025 ➔ Nov 2026

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Real-world outcomes of topical 2% simvastatin/2% cholesterol therapy for disseminated superficial actinic porokeratosis: a service evaluation (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence

Simvastatin and non-segmental vitiligo: A new potential treatment option ? (EADV 2026) - No abstract available

Dermatology • Immunology • Vitiligo

Hepatic fibrosis extracellular matrix stiffness induces abnormal maturation of dendritic cell via AMPK inhibition-mediated cholesterol accumulation. (PubMed, Mater Today Bio) - "In mouse models, combined treatment with pirfenidone and simvastatin reduced liver stiffness and collagen deposition, and restored immune tolerance by correcting DC cholesterol metabolism. Our study identifies a mechanometabolic pathway linking matrix stiffness to DC dysfunction, providing a promising immunometabolic strategy for antifibrotic therapy."

Journal • Fibrosis • Hepatology • Immunology • ABCG1 • AMPK • IL10

ApoE deficiency in mice exacerbates antigen-induced arthritis, alters HDL anti-oxidant capacity and promotes macrophage activation which are reversed by simvastatin treatment. (PubMed, Biochim Biophys Acta Mol Cell Biol Lipids) - "Additionally, treatment of ApoE KO mice with simvastatin limited the M1-associated cell surface markers on spleen macrophages and reduced arthritic joint swelling. Collectively, our findings support further investigation of lipid-modifying strategies in the context of inflammatory arthritis associated with dyslipidemia."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Dyslipidemia • Immunology • Inflammation • Inflammatory Arthritis • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • APOE • PON1

Quercetin alleviates statin-induced myopathy in adult male rats: insights into the role of oxidative stress, apoptosis, and autophagy-related gene expression (LC3 and LAMP2). (PubMed, J Mol Histol) - "This study assessed the effect of quercetin on simvastatin-induced myopathy in adult male rats, focusing on the modulation of autophagy-apoptosis crosstalk...These findings suggest that quercetin may represent a promising adjuvant strategy for mitigating statin-associated myopathy. Further studies evaluating autophagic flux at the protein level are warranted to clarify the underlying mechanisms."

Journal • Preclinical • Muscular Atrophy • Myositis • BAX • CASP3 • LAMP2

Effect of simvastatin versus calcium hydroxide intracanal medications on postoperative pain and cytokine modulation in symptomatic apical periodontitis: a randomized controlled trial. (PubMed, BMC Oral Health) - P=N/A | "Simvastatin demonstrated comparable efficacy to Ca(OH)₂ in managing postoperative pain and reducing inflammatory mediators, suggesting its potential as an alternative intracanal medication. While Ca(OH)₂ remains the gold standard intracanal medicament, simvastatin demonstrated promising anti-inflammatory effects that may contribute to reduced postoperative pain and decreased levels of pro-inflammatory mediators. Future investigations incorporating larger sample sizes, extended follow-up durations, different simvastatin concentrations, alternative delivery vehicles, long-term radiographic healing outcomes, effect on other inflammatory mediators, and its applicability in different types of apical periodontitis or retreatment cases are essential to corroborate these outcomes and evaluate the expanded clinical utility of simvastatin within endodontic therapy."

Clinical • Journal • Dental Disorders • Pain • Periodontitis • CXCL8 • IL6

Polyphenol-Rich Opuntia ficus-indica Cladodes: An Integrated Metabolomic, In Vivo and In Silico Study Supporting Their Hypolipidemic and Hepatoprotective Effects. (PubMed, Nutrients) - " Hyperlipidemic mice fed a high-fat diet (HFD) were treated with OCE, while molecular docking was performed on ten major annotated phytochemicals against twelve key proteins involved in lipid metabolism and cholesterol homeostasis, including HMGCR, FAS, PPARα, PCSK9, and NPC1L1, using simvastatin as the reference compound...Molecular docking supported the potential contribution of these phytochemicals to the regulation of lipid metabolism through favorable interactions with multiple therapeutic targets, while ADMET prediction suggested an overall favorable pharmacokinetic and toxicity profile despite the lower intestinal permeability predicted for glycosylated derivatives. Overall, these findings support O. ficus-indica cladodes as a promising source of dietary bioactive compounds with potential applications in the nutritional management and prevention of hyperlipidemia and related cardiometabolic disorders."

Journal • Preclinical • Cardiovascular • Dyslipidemia • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • PPARA

HJURP-Yap1-Wisp1 Axis Drives Lung Adenocarcinoma Brainmetastasis Through Tumor-Supportive Microglial Reprogramming (IASLC-WCLC 2026) - "HJURP acts beyond its histone chaperone role to stabilize YAP1, inducing WISP1 secretion which educates microglia via Integrin-MAPK signaling. These findings reveal a critical mechanism of tumor-microglia crosstalk and suggest that Simvastatin intervention targeting the HJURP-YAP1-WISP1 axis represents a promising therapeutic strategy for overcoming lung adenocarcinoma brain metastasis."

Brain Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • ITGB3 • YAP1

Ny behandling af porokeratose med magistrel simvastatincreme. (PubMed, Ugeskr Laeger) - No abstract available

Journal • TINCR

TSTIH: Topical Simvastatin for Treating Infantile Hemangioma (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Joyce Teng | Trial completion date: Dec 2025 ➔ Jun 2029 | Trial primary completion date: Jul 2025 ➔ Mar 2028

Trial completion date • Trial primary completion date

The Influence of Simvastatin on the Osteogenic Differentiation Induced by Calcium Silicate-Based Cements. (PubMed, Eur Endod J) - "Hydraulic calcium silicate-based cements exhibited distinct effects on the expression of differentiation-related genes, while showing a comparable influence on mineralisation nodule deposition. These findings suggest material-specific biological responses when the cements are combined with simvastatin."

Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • COL1A1

Heterogeneity of Treatment Effect by Molecular Endotype in Acute Respiratory Distress Syndrome: A Systematic Review. (PubMed, Ann Am Thorac Soc) - "Endotyping in ARDS reliably identifies biologically distinct patient groups, but evidence that endotypes consistently modify treatment response is sparse and of generally low credibility. Progress toward endotype-guided therapy will require multi-omic molecular characterization, prospective trials with pre-specified interaction hypotheses, and real-time endotype assignment."

Heterogeneity • Journal • Acute Respiratory Distress Syndrome • Critical care • Pulmonary Disease • Respiratory Diseases

Verification of a Physiologically-based Pharmacokinetic Model for Predicting CYP3A4-mediated Simvastatin and Simvastatin Acid Drug-drug Interactions. (PubMed, AAPS J) - "In the current work, we used a static approach to define simvastatin CYP3A4 parameters, using clinical data with index substrate midazolam; estimated simvastatin Fg,CYP3A4 and fm,CYP3A4 were ~ 0.4 and ~ 0.9, respectively. The simvastatin-GFJ effect was explained by inhibition of this intestinal simvastatin acid formation, along with CYP3A4 inhibition. The unique effect of food on the simvastatin acid:simvastatin exposure ratio could also be replicated using this PBPK model."

Journal • PK/PD data • CYP3A4

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis (clinicaltrials.gov) - P2 | N=52 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Dec 2027 ➔ Jul 2026

Trial completion • Trial completion date • Fibrosis • Gastroenterology • Germ Cell Tumors • Hepatocellular Cancer • Hepatology • Immunology • Liver Cancer • Liver Cirrhosis • Oncology • Solid Tumor

Protosappanin A Alleviates Atherosclerosis by Regulating the MDM2/GPX4 Axis-Mediated Endothelial Ferroptosis. (PubMed, Phytother Res) - "To address this, ApoE-/- mice were fed a high-fat diet for 16 weeks to induce atherosclerosis, and PTA or simvastatin was administered daily from Week 4 through Week 16 (12 weeks of intervention)...Overexpression of MDM2 activated endothelial ferroptosis and reversed the protective effects of PTA both in vitro and in vivo. Collectively, these findings demonstrate that PTA alleviates AS by suppressing endothelial ferroptosis via the MDM2/GPX4 axis."

Journal • Atherosclerosis • Cardiovascular • APOE • GPX4 • ICAM1 • MDM2 • VCAM1

Involvement of Protein Kinase C Delta and Monocarboxylate Transporter 4 in the Development of Statin-Induced Cytotoxicity in a Rhabdomyosarcoma-Derived Cell Line. (PubMed, Biol Pharm Bull) - "Treatment with simvastatin, atorvastatin, and fluvastatin reduced RD cell viability in a concentration-dependent manner. Tamoxifen, a clinically available drug with PKC inhibitory activity, including against the δ isoform, attenuated simvastatin-induced cell injury, paralleling the effects of BIM. Collectively, our findings demonstrate that PKCδ contributes to statin-induced cytotoxicity in rhabdomyosarcoma cells, at least in part by regulating MCT4 expression."

Journal • Preclinical • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor

RAS/MAPK pathway modulation with simvastatin in children with Noonan syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial (ESPE 2026) - No abstract available

Clinical • P3 data • Genetic Disorders

Simvastatin-Loaded Nanoparticles Reduce Ischemia-Reperfusion Injury Following Rat Hindlimb Ischemia-Reperfusion (AHA 2026) - "Abstract is embargoed at this time."

Preclinical • Cardiovascular • Reperfusion Injury

Study on mechanism of Wendan Decoction in intervening in nonalcoholic fatty liver disease based on proteomics and network pharmacology (PubMed, Zhongguo Zhong Yao Za Zhi) - "A mouse NAFLD model was established using a high-fat diet, and the mice were randomly divided into a blank control group, a model group, a positive drug group(simvastatin, 3.03 mg·kg~(-1)), and low-(3.035 g·kg~(-1)), medium-(6.07 g·kg~(-1)), and high-dose(12.14 g·kg~(-1)) WDD groups, with intervention lasting for 6 weeks...Molecular biology validation showed that WDD significantly regulated the mRNA expression of sterol regulatory element-binding protein-1c(SREBP-1c), fatty acid synthase(FASN), carnitine palmitoyl transferase 1A(CPT1A), acyl-CoA oxidase 1(ACOX1), and PPARα, as well as protein expression of PPARα, CPT1A, and PPARγ in mouse liver tissue. These results suggested that WDD might exert a multi-component, multi-target, and multi-pathway synergistic effect to improve lipid metabolism disorders and inflammatory responses with the PPAR signaling pathway as the central hub, thereby alleviating NAFLD progression."

Journal • Addiction (Opioid and Alcohol) • Atherosclerosis • Cardiovascular • Dyslipidemia • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • ACOX1 • CPT1A • FASN • IL1B • IL6 • PPARA • PPARG • TNFA

Mechanism of total saponins from Allium macrostemon in reducing inflammatory infiltration of aortic macrophages and anti-atherosclerosis in ApoE~(-/-) mice via regulating NF-κB signaling pathway (PubMed, Zhongguo Zhong Yao Za Zhi) - "AS animal models were established by 50 ApoE~(-/-) mice fed with a high-fat diet and randomized into a model group, low-, medium-, and high-dose SAMB groups, and a simvastatin group...SAMB reduces inflammatory factors in vascular tissue of AS mice and inhibits macrophage infiltration in aortic plaques, exerting anti-atherosclerotic plaque formation effects. Its mechanism may be related to inhibiting the NF-κB-related pathway in macrophages."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Oncology • APOE • CCL2 • IL1B • IL6 • NFKBIA • RELA • TNFA